This article has been updated from a previous version to include additional comments from Insight Genetics.

By Ben Butkus

Molecular diagnostics firm Insight Genetics said last week that it has inked an exclusive worldwide licensing agreement with St. Jude Children's Research Hospital for mutations in the anaplastic lymphoma kinase gene that confer resistance to ALK inhibitors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.